HRT and Blood Clots: What to Ask Before Someone Hands You a Prescription

You want help with the hot flashes, the sleep disruption, the brain fog and the mood swings.

But one phrase keeps stopping you: blood clot risk.

Maybe your mother had a stroke. Maybe your aunt had a pulmonary embolism. Maybe you had a clot yourself. Maybe nobody in your family had one, but you read enough online to feel like HRT is either relief or danger, with no middle ground.

That is exactly where a better clinical conversation should begin.

A blood clot risk conversation is not a box to check. It is the safety map before hormone therapy.

This article is not a substitute for that conversation, and you should not start, stop, or change any hormone regimen based on an article alone. What it will do is help you understand what a thorough risk review covers, what can happen through a telemedicine visit, and what questions are worth asking before any prescription is written.

The Short Answer

Yes, much of a blood clot risk review can begin through telemedicine. A clinician can review your personal history, family history, medications, blood pressure, migraine history, prior clot history, smoking status, and route options during a telehealth visit. Labs or medical records may be appropriate depending on what the history shows. Some situations require collaboration with other specialists or providers before HRT is considered.

What telemedicine cannot do is evaluate active symptoms of a clot, stroke, or pulmonary embolism. If you have symptoms that suggest an active event, that is not a telemedicine situation. That is an emergency.

What Blood Clot Risk Actually Means

When clinicians talk about blood clot risk in the context of HRT, they are usually discussing several related but distinct concerns.

A deep vein thrombosis, or DVT, is a clot that forms in a deep vein, usually in the leg. A pulmonary embolism, or PE, is when a clot travels to the lungs - which can be life-threatening. Venous thromboembolism, or VTE, is the term that covers both DVT and PE together.

Stroke risk is a related but separate conversation. Ischemic stroke involves a blockage in blood flow to the brain. Some hormonal and cardiovascular risk factors overlap with both VTE and stroke risk, which is why blood pressure, migraine history with aura, and smoking status all come up in the HRT risk conversation.

The difference between personal history and family history matters here. A personal history of DVT, PE, or stroke is a more significant clinical variable than family history - though family history is still relevant and worth reviewing carefully.

A clot risk review is not just "Did anyone in your family have a stroke?" It is a pattern review that covers your full history, your current health status, your medications, and the route of hormone therapy being considered.

Why Women Are Still Confused About HRT Risk

If you have heard conflicting things about HRT and blood clots for the last twenty years, there is a reason for that - and it is not because the science was always unclear.

In 2002, the Women's Health Initiative published findings that led to widespread headlines about HRT increasing the risk of breast cancer, heart disease, and blood clots. Millions of women stopped HRT. Prescriptions dropped sharply. Many physicians stopped offering it. Many women were told simply: no hormones.

What did not travel as far as those headlines was the nuance. The WHI studied older postmenopausal women - average age 63 - using oral conjugated equine estrogen combined with a synthetic progestin, medroxyprogesterone acetate. The findings were specific to that population, that formulation, and that route. They were not findings that applied equally to a 47-year-old woman in perimenopause using a transdermal estradiol patch.

The risk conversation also did not evolve publicly the way it evolved in the medical literature. Subsequent research clarified that timing matters - starting HRT closer to menopause onset may carry a different risk profile than starting it years later. Route matters - transdermal estrogen carries a different clotting and cardiovascular signal than oral estrogen. Formulation matters - micronized progesterone has a different profile than older synthetic progestins. Age and individual health history matter.

None of that complexity made it into the "no hormones" message many women received from their providers or read online.

So if you have spent twenty years being told HRT is dangerous, and you are now reading that it may be appropriate with the right evaluation - both things can be true. The risk is real and requires a real conversation. The oversimplified "no" was not the full picture either.

What Can Be Reviewed Through Telemedicine

A thorough telemedicine visit can cover most of what a blood clot risk assessment requires when there is no active emergency and the history is not unusually complex.

This includes personal history of DVT, PE, stroke, or TIA; family history of clotting events or stroke; current blood pressure and how well it is controlled; smoking status; migraine history including whether migraines occur with aura; body composition context; kidney or liver disease history; cancer history; recent surgery or prolonged immobility; autoimmune or inflammatory conditions; current medications including anticoagulants; any clots that occurred during pregnancy; known thrombophilia or clotting disorder; prior reactions to hormones; and current symptoms that might indicate an ongoing concern.

That is a substantial review that shapes the route conversation, the dosing discussion, and whether additional labs or records are needed before moving forward.

What May Require Labs, Records, or Specialist Input

Not every situation can be fully assessed through history alone.

A prior documented clot or PE may require records to understand the circumstances - whether it was provoked or unprovoked, what treatment was used, and whether there is ongoing anticoagulation. A known thrombophilia may require coordination with hematology or a review of prior workup. An unclear clotting history or strong family history with unknown details may require additional evaluation before a route decision is made. Recurrent pregnancy loss in some contexts may prompt a discussion about clotting workup. Uncontrolled hypertension, complex cardiovascular history, or active or recent cancer history may require input from the appropriate specialist before HRT is considered.

More testing is not always better. The right testing depends on the history. A clinician who orders a full thrombophilia panel for every woman considering HRT is not practicing more carefully. They are practicing without clinical reasoning.

Why Route Comes Up in the Clot Risk Conversation

Not all estrogen delivery routes carry the same clotting risk signal, and this distinction matters when a woman has risk factors in her history.

Oral estrogen is processed through the liver before it reaches the bloodstream. This first-pass effect activates certain clotting proteins. ACOG has noted that oral estrogen may have a prothrombotic effect through this mechanism. Transdermal estrogen, including patches, gels, and sprays, bypasses the liver's first pass and does not produce the same degree of clotting protein activation. The Menopause Society notes that transdermal routes and lower doses may be associated with decreased VTE and stroke risk compared to oral routes.

This does not mean a patch carries no risk or is appropriate for everyone. It means route matters, and that conversation should be part of any HRT safety review when clotting history or risk factors are present.

When Telemedicine Is Not the Right Setting

This section is not optional and not meant to create fear. It is a safety map.

If you have any of the following symptoms, do not schedule a telehealth appointment first. Seek urgent or emergency care.

New one-sided leg swelling or pain. Chest pain. Shortness of breath. Coughing up blood. Sudden severe headache unlike your usual headaches. Weakness or numbness on one side of the body. Facial drooping. Difficulty speaking or understanding speech. Sudden vision changes.

If you have symptoms of a possible clot, PE, or stroke, do not book a telehealth consult first. Seek urgent or emergency care.

The Neurodivergent and Allostatic Load Layer

For high-masking women, autistic women, ADHD women, and women with alexithymia or interoceptive differences, this safety conversation requires an additional layer of clinical attention.

Women with interoception differences may have difficulty identifying what counts as "new," "severe," or "different" in their body. The distinction between a usual leg ache and something worth reporting, or between typical fatigue and unusual shortness of breath, can be genuinely difficult to make when the body's signals arrive quietly or inconsistently. This is not carelessness. It is a real difference in how the nervous system communicates.

Some women do not miss symptoms because they are careless. They miss them because their body signals arrive in a language nobody taught them to translate.

Chronic allostatic load - from hypervigilance, masking, trauma history, or years of sensory overload - can also affect blood pressure, inflammation, and cardiovascular markers in ways that belong in the risk conversation. A clinician who is taking a complete picture should ask structured questions rather than relying on "let me know if something feels off."

Questions to Ask Before Starting HRT

These are worth bringing directly to your clinician before any prescription is written.

What is in my personal history that affects my clot or stroke risk? How does my family history factor into this? Does my migraine history matter, and if so how? Is my blood pressure controlled enough to proceed? Does my smoking status or body composition context affect the route discussion? Would transdermal estrogen be preferred in my situation? Do I need labs or medical records before we move forward? Do I need input from hematology, cardiology, or my primary care provider? What symptoms should prompt me to seek urgent care after starting? How will we monitor after I begin?

When to Escalate To A Healthcare Professional

If you have been offered HRT without a conversation that covered the topics above, that conversation is incomplete.

If you avoided HRT because someone mentioned blood clots and the conversation stopped there without a route discussion, a history review, or a risk assessment, that was not enough information to make a decision.

If you are physically located in California, D.C., Georgia, Kentucky, Maryland, Ohio, Texas or Virginia at the time of your visit, the Reset Foundations Consult is where we review your symptoms, history, baseline labs, HRT questions, medication concerns, blood clot risk factors and your next clinical step.

Take the Next Step

Book the Reset Foundations Consult

Frequently Asked Questions

• Can I get a blood clot risk assessment for HRT through telemedicine? Yes, much of the risk review can begin through telemedicine. A clinician can review your personal history, family history, medications, blood pressure, migraine history, prior clot history, and route options during a telehealth visit. Some situations may require labs, medical records, or specialist input before HRT is appropriate.

• Can telemedicine rule out an active blood clot? No. Telemedicine is not the right setting to evaluate active symptoms of a DVT, PE, or stroke. Symptoms such as one-sided leg swelling, chest pain, shortness of breath, coughing blood, facial droop, sudden weakness, difficulty speaking, or sudden vision changes need urgent or emergency evaluation, not a telehealth appointment.

• Does an estrogen patch have less clot risk than pills? Transdermal estrogen is often discussed when clot risk is a concern because it bypasses the liver's first-pass effect. ACOG has noted that oral estrogen may have a prothrombotic effect while transdermal estrogen may have little or no effect on prothrombotic substances. That does not mean a patch is risk-free or appropriate for everyone. Route matters, and that conversation should be part of any HRT safety review.

• Does a family history of blood clots mean I cannot use HRT? Not automatically. Family history is relevant but it is not the same as personal history. It should prompt a careful review of the details - who had the clot, under what circumstances, whether a thrombophilia was identified, and what your own risk factors look like. That review determines next steps, not a blanket answer.

• Do I need a blood test for clotting before starting HRT? Not always. More testing is not always better - the right testing depends on your personal history, family history, and clinical risk factors. Some women may need records, labs, or specialist input. Others may not. A clinician should be able to explain why specific testing is or is not indicated for your situation.

• What if I had a pulmonary embolism or DVT in the past? A prior PE or DVT needs individualized clinical review. Do not assume the answer is automatic in either direction. Your clinician will likely need records about the event, details about whether it was provoked or unprovoked, your current medications, and possibly input from hematology or another specialist before any HRT decision is made.

• Is HRT ever considered when someone has clot risk factors? Sometimes, depending on the specific risk factors, route, dose, timing, symptom severity, and clinical goals. Some women may not be candidates. Others may need a very careful route and risk discussion before proceeding. This is not a one-size answer. It requires individualized medical review.

• What should I ask before starting HRT if I am worried about stroke? Ask how your blood pressure, migraine history, smoking status, family history, personal clot or stroke history, route of estrogen delivery, and current medications each affect your stroke risk. Also ask what symptoms should prompt you to seek urgent care after starting, and how you will be monitored.

Sources

• ACOG Committee Opinion No. 556: Postmenopausal Estrogen Therapy - Route of Administration and Risk of Venous Thromboembolism. Obstetrics and Gynecology. 2013. acog.org

• The Menopause Society (formerly NAMS). The 2022 Hormone Therapy Position Statement. Menopause. 2022. DOI: 10.1097/GME.0000000000002028

• Canonico M et al. Hormone therapy and venous thromboembolism among postmenopausal women: the ESTHER study. Circulation. 2007. DOI: 10.1161/CIRCULATIONAHA.106.642280

• ACOG. Hormone Therapy for Menopause FAQ. acog.org/womens-health/faqs/hormone-therapy-for-menopause

Dr. Stacey Denise provides clinical care to patients physically located in California, D.C., Georgia, Kentucky, Maryland, Ohio, Texas or Virginia at the time of the visit.

This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided is intended to support informed conversations with your healthcare provider, not to replace clinical evaluation. Individual health decisions should be made in consultation with a licensed clinician who has reviewed your personal history, symptoms, labs, and medications. If you are experiencing symptoms that may require urgent attention, seek care from an appropriate medical provider.